

Ann Lloyd CBE, Cadeirydd | Chair

☎ 01633 435 957

✉ Ann.Lloyd@wales.nhs.uk

Nicola Prygodzicz, Prif Weithredwr | Chief Executive

☎ 01633 435 958 🐦 CEOabuhb

✉ Nicola.Prygodzicz@wales.nhs.uk



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Aneurin Bevan
University Health Board

Our ref: **FOI 23-587**

Friday, 01 March 2024

Your request

You requested the following:

1. Please provide the total number of patients treated in the last 6 months for:
 - Polycythaemia Vera (ICD10 code D45)
 - Myelofibrosis (ICD10 code D47.4)
 - Myelofibrosis (ICD10 code D47.4) patients aged 65 and older
2. How many patients were treated in the past 6 months (for any disease) with:
 - Ruxolitinib
 - Fedratinib
 - Interferon (any type)
3. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:
 - Polycythaemia Vera (ICD10 code D45)
 - Myelofibrosis (ICD10 code D47.4)
4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
 - Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
 - Of these patients, how many were treated in the past 6 months with Interferon therapy?
 - Of these patients, how many have received no active treatment in the past 6 months?
5. How many Polycythaemia Vera (ICD10 code D45) patients has your trust diagnosed in the past 3 years?
 - Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
 - Of these patients, how many were treated in the past 6 months with Interferon therapy?
6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

Our response

I can confirm that the Health Board has completed a search of its records and has established that it does hold some information in relation to your request, as set out below:

Bwrdd Iechyd Prifysgol Aneurin Bevan
Pencadlys, Ysbyty Sant Cadog
Ffordd Y Lodj, Caerllion, Casnewydd NP18 3XQ

☎ 01633 436 700 📘 BwrddIechydPrifysgol 🐦 BIPAneurinBevan

Dyfodol Clinigol
Clinical Futures

☎ 01633 436 700 📘 AneurinBevanHealthBoard 🐦 AneurinBevanUHB

Aneurin Bevan University Health Board
Headquarters, St Cadoc's Hospital
Lodge Road, Caerleon, Newport NP18 3XQ

Rydym yn croesawu gohebiaeth yn Gymraeg a byddwn yn ymateb yn Gymraeg heb oedi.
Bwrdd Iechyd Prifysgol Aneurin Bevan yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Aneurin Bevan.

We welcome correspondence in Welsh and we will respond in Welsh without delay.
Aneurin Bevan University Health Board is the operational name of Aneurin Bevan University Local Health Board.

1. Our response is contained in the table below:

The number of individual patients with a primary diagnosis (the main condition treated or investigated) of D45 or D474 attending outpatients or with an inpatient or day case stay, April to September 2023.

Patients with a primary diagnosis (the main condition treated or investigated) of D45 or D474 attending outpatients or with an inpatient or day case stay, April to September 2023.		
ICD-10 code	Outpatients	Inpatients and Daycases
D45	172	0
D474	38	5
D474 (Aged over 65)	35	5

For questions 2 and 3, we are not able to provide information on the treatment drugs prescribed to individual patients as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.

4. Our part response is contained in the table below:

Patients with a primary diagnosis of Myelofibrosis (D474) who have had an outpatient or with an inpatient or day case stay, for the financial years 2020-21 to 2022-23		
Financial Year	Outpatients	Inpatients
2020/21	37	5
2021/22	39	4
2022/23	43	4

Please note that the information provided is the number of individual patients who have had an outpatient appointment or inpatient stay with a primary diagnosis of these conditions in each of the financial years and it may not be when they were first diagnosed with the condition. Any patients whose condition is managed solely in primary care (GP surgeries; which are independent contractors) or by another Health Board will not be included.

We are not able to provide information on the treatment prescribed to patients diagnosed with Myelofibrosis as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test

5. Our part response is contained in the table below:

Patients with a primary diagnosis of Polycythaemia (D45) who have had an outpatient or with an inpatient or day case stay, for the financial years 2020-21 to 2022-23		
Financial Year	Outpatients	Inpatients
2020/2021	212	5

2021/2022	217	0
2022/2023	198	4

We are not able to provide information on the treatment prescribed to patients diagnosed with Polycythaemia Vera as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.

6. We do not currently take part in any trials for myelofibrosis.